These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18604711)

  • 1. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
    Ross DM; Hughes TP
    Leuk Lymphoma; 2008 Jul; 49(7):1230-1. PubMed ID: 18604711
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
    Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
    Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.
    Saulnier PJ; Dalbiès F; Berthou C; Guilhot F; Bourmeyster N; Chomel JC; Thuran A
    Leuk Lymphoma; 2008 Apr; 49(4):815-6. PubMed ID: 18398751
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
    Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract]   [Full Text] [Related]  

  • 10. Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
    Oliveira GA; Costa ES; Freitas MS; Dutra FF; Maia SF; Guerra MC; Tabernero MD; Borojevic R; Otazu IB; Silva JL
    Braz J Med Biol Res; 2010 Jun; 43(6):580-4. PubMed ID: 20396859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.
    Burger JA; Schmitt-Gräff A; Bürkle A; Seiler L; Finke J
    Leuk Lymphoma; 2006 Nov; 47(11):2427-30. PubMed ID: 17107924
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
    Verma D; Kantarjian H; Jain N; Cortes J
    Leuk Lymphoma; 2008 Jul; 49(7):1399-402. PubMed ID: 18452066
    [No Abstract]   [Full Text] [Related]  

  • 15. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
    Einwallner E; Jaeger E; Mitterbauer-Hohendanner G; Bilban M; Simonitsch-Klupp I; Steiner I; Pernicka E; Hoermann G; Herndlhofer S; Sillaber C; Valent P; Schwarzinger I
    Stem Cells Dev; 2013 Dec; 22(23):3043-51. PubMed ID: 23883175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
    Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
    Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
    Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
    Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
    Li YF; Liu X; Liu DS; Din BH; Zhu JB
    Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
    [No Abstract]   [Full Text] [Related]  

  • 20. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
    Brümmendorf TH; Ersöz I; Hartmann U; Bartolovic K; Balabanov S; Wahl A; Paschka P; Kreil S; Lahaye T; Berger U; Gschaidmeier H; Bokemeyer C; Hehlmann R; Dietz K; Lansdorp PM; Kanz L; Hochhaus A
    Blood; 2003 Jan; 101(1):375-6. PubMed ID: 12485943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.